Latest News and Press Releases

De kliniske resultater af et fase III studie med ALKs nye tablet til behandling af træpollenallergi (birk, el og hassel) er blandt de mest signifikante, der nogensinde er vist i studier med...

Leading allergy researchers present Phase III data on tree SLIT-tablet at EAACI Annual Congress in MunichBirch pollen-based product shown to be effective against multiple tree allergiesEffect shown to...

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk.   Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has...

Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has improved its full-year financial outlook. Q1 saw good progress with ALK’s four...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første tre måneder (Q1) 2018 fredag den 4. maj 2018. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...

               On Friday, 4 May 2018, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its interim report for the three months ended 31 March 2018. ALK will host a meeting for analysts and...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) har i dag meddelt, at selskabets partner i Japan, Torii Pharmaceutical Co., Ltd, har indgået en prisaftale med de japanske myndigheder for...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has agreed a price with authorities and secured a listing on Japan’s National...

ALK gains rights to market Rellergen’s Bio-IC technology in more than 190 hospitals across ChinaBio-IC technology offers fast, convenient and inexpensive allergy diagnosis on siteChina’s allergy...

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...